Tina Liedtky: Thermo Fisher Scientific Launches New Test to Help Guide Tacrolimus Dosing
Tina Liedtky, President of the Transplant Diagnostics Division at Thermo Fisher Scientific, shared a post on LinkedIn:
“In transplant medicine, every patient is unique. And healthcare teams need tools that enable them to provide personalized care.
To this end, I am excited to share that, today, Thermo Fisher Scientific launched a new laboratory developed test to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug that can help lower the risk of transplant rejection.
The right tacrolimus dose will vary from patient to patient.
With the new TacroType Pharmacogenetic Test, clinicians can better understand how their patient is likely to metabolize tacrolimus and respond to certain therapies.
This pharmacogenetic information is invaluable.
Learn more about what the new TacroType Pharmacogenetic Test means for patient care by reading the press release.”
Stay updated with Hemostasis Today.
-
Mar 2, 2026, 15:08Joseph Italiano: Exploring the Intersection of Megakaryocyte Biology and Chronic Kidney Disease
-
Mar 2, 2026, 13:42Michael Makris: How Early Can Hemlibra Be Started?
-
Mar 2, 2026, 13:39Platelets Journal Welcomes Sarah Westbury as Principal Editor to the Editorial Board
-
Mar 2, 2026, 11:10AbQader Bedil: A Practical Diagnostic Workflow for Von Willebrand Disease
-
Mar 2, 2026, 11:06Advancing Visibility, Research, and Equitable Care on Rare Disease Day – WFH
-
Mar 2, 2026, 11:02Jecko Thachil: Exploring the Origins and Meaning of the Term Hemophilia
-
Mar 2, 2026, 10:56Emmanuel J Favaloro: The Most Popular Downloaded Papers in 2025 from Seminars in Thrombosis and Hemostasis
-
Mar 2, 2026, 10:48Akinchan Bhardwaj: Key Genomic Insights Transforming Coronary Artery Disease Prevention
-
Mar 2, 2026, 08:07Michael Makris: Exploring ADAMTS13, vWF Imbalance, and Endotheliopathy in Ischemic Stroke